Table 2 Percentage change in FES uptake from baseline to day 14 for the two different dose cohorts
Elacestrant dose cohort | |||
|---|---|---|---|
Parameter | 200/400 mg (N = 8) | 400 mg (N = 8) | Overall (N = 16) |
Number evaluated, n (%) | 8 (100)a | 8 (100) | 16 (100) |
Mean (SD), % | − 82.6 (15.5) | − 86.0 (10.2) | − 84.3 (12.8) |
Median (Q1, Q3), % | − 89.1 (− 94.2, − 67.6) | − 88.7 (− 94.1, − 79.5) | − 89.1 (− 94.1, − 75.1) |